WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer. Dr. Kaufmann succeeds Christopher J. Silber, M.D.
"Dr. Kaufmann brings a wealth of experience that will be invaluable to the Vigil team," said Ivana Magov?evi?-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. "As we further the development of both iluzanebart and VG-3927, we will benefit from her extensive background in neurological and rare diseases, as well as her proven expertise in both domestic and global drug development."
Dr. Kaufmann is an accomplished biotech executive joining Vigil Neuroscience from Affinia Therapeutics where she served as Chief Medical Officer leading medical, clinical, patient advocacy and regulatory strategy. Prior to Affinia Therapeutics, Dr. Kaufmann held the position of Senior Vice President, Clinical Development, Translational Medicine & Analytics at Novartis Gene Therapies where she led the company's global clinical development strategy including global approvals of Zolgensma®. She has also served as Vice President, Translational Medicine at AveXis (acquired by Novartis), and Head, Office of Rare Diseases Research at the National Institutes of Health. Dr. Kaufmann holds an M.S. in biostatistics from Columbia University and an M.D. from the University of Bonn.
"I am honored and excited to join Vigil, a company at the forefront of developing innovative treatments for rare and common neurological diseases," said Petra Kaufmann, M.D., M.S., F.A.A.N, Chief Medical Officer of Vigil. "I look forward to leading ...